Please assess the completion status of the following clinical trial:

Trial Title: Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed diagnosis of locally advanced (unresectable Stage III) or metastatic (Stage IV) melanoma not amenable to local therapy~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* At least one measurable lesion~* Adequate organ function~Exclusion criteria:~* Prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-PD ligand-1 (PD-L1), anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agent~* Is currently participating or has participated in a study with an investigational compound or device within 30 days, or 5X half-life of the investigational compound, whichever is longer, of initial dosing on this study~* Chemotherapy, targeted small molecule therapy, radiotherapy, or biological cancer therapy (including monoclonal antibodies) within 4 weeks prior to the first dose of trial treatment, or not recovered (\<= Grade 1 or baseline) from adverse events due to a previously administered agent~* Expected to require any other form of systemic or localized antineoplastic therapy while in study~* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis~* Documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents~* Receiving systemic steroid therapy or any other form of immunosuppressive therapy within 1 week prior to the first dose of study treatment~* Received a live vaccine within 4 weeks prior to the first dose of trial treatment~* Has a known hypersensitivity to the components of the study drug or another monoclonal antibody~* History or evidence of active pneumonitis~* Human immunodeficiency virus (HIV)-positive~* Has known history of active Hepatitis B or C~* Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial treatment through 120 days after the last dose of study medication

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced Cutaneous Melanoma (Type: EXPERIMENTAL): Participants with advanced cutaneous melanoma received pembrolizumab, 2 mg/kg, intravenously (IV) over 30 minutes on Day 1 of each 3-week dosing cycle (Q3W).
- Advanced Mucosal Melanoma (Type: EXPERIMENTAL): Participants with advanced mucosal melanoma received pembrolizumab, 2 mg/kg, IV over 30 minutes on Day 1 Q3W.

Based on this trial design, predict the completion outcome and termination type (if applicable).